INTRODUCTION
Neuro bromatosis type 1 (NF-1) is a multisystemic genetic disorder that displays important cutaneous manifestations such as café-aulait spots, freckles and neuro bromas. Despite variable clinical expression, mutation of the NF-1 gene is considered to be the most common de novo spontaneous autosomal dominant genetic alteration in human beings, with complete penetrance. 1 e incidence of NF-1 is approximately one in 2,500 births, a ecting all races. About 80,000 cases are estimated to exist currently in Brazil, and about 1.5 million worldwide. 1, 2 e NF-1 gene is located on the long arm of chromosome 17, and more precisely, in the 17q11.2 band. is gene codes for neuro bromin, a protein that acts during nervous tissue growth remodeling. 2 Recent studies have also demonstrated the presence of neuro bromin on the walls of vascular endothelial cells and in vascular smooth muscle cells.
ed a systematic search in the PubMed, Cochrane Library, Lilacs (Literatura Latino Americana e do Caribe em Ciências da Saúde) and SciELO (Scienti c Electronic Library Online) databases. e results obtained are shown in Table 1 .
CASE REPORT
An eight-month-old Afro-descendant girl was referred to the emergency room of the University Hospital due to convulsive 5-10 minute seizures characterized by mucosal pallor, clonic movement to the right and right-sided head version. e patient presented postictal somnolence. No fever was observed at the time of the seizures. A cerebrospinal uid tap yielded normal results. Brain magnetic resonance imaging (MRI) revealed asymmetry of the hemispheres, with hemiatrophy on the left ( Figure 1A) and signs of internal carotid occlusion in the supraclinoid and basilar portions, with marked collateral circulation through perforating vessels, with a moyamoya pattern (Figures 1B to 1F ). Hemiparesis was most evident in the right upper limb.
A diagnosis of ischemic stroke was made based on the clinical and radiological ndings. rombophilia testing was negative. At one year and eight months of age, she was referred to the medical genetics service due to the presence of skin lesions, delayed motor development and facial dysmorphism. Physical examination revealed several café-au-lait spots (larger than 0.5 cm) and cutaneous neuro bromas. At two years of age, the patient presented facial paralysis with slight facial asymmetry of peripheral pattern. Her mother also ful lled the diagnostic criteria for NF-1. e girl is the rst child of non-consanguineous healthy parents. Regarding her neuropsychomotor development, she was able to hold her head up at the age of seven months, spoke her rst words at the age of one year and seven months and sat up unsupported at the age of one year and nine months. e child is currently under clinical surveillance, and persists with motor de cits. istics must be present: I) six or more café-au-lait spots with a diameter of about 5 mm in prepubertal individuals, or with a diameter of more than 15 mm in postpubertal individuals; II) two or more neuro bromas of any type or one plexiform neuro broma, based on clinical and histological parameters; III) freckles in an axillary or inguinal region; IV) optic glioma; V) two or more Lisch nodules (pigmented iris hamartomas); VI) a distinct bone lesion such as pseudarthrosis of a long bone or dysplasia of the sphenoid wing; and VII) a rst-degree relative with NF-1 ful lling the above criteria. A variety of vascular lesions have been observed in patients with NF-1, such as arterial occlusion, aneurysms, pseudoaneurysms, stenosis, stulae and ruptures. Although the arterial system is more commonly a ected, lesions of the venous system have also been observed. 3 e main characteristic of vascular lesions in patients with NF-1 is occlusion of the lumen and hyperplasia of the intima wall. Based on microscopic evaluation of the a ected vessels, it has been proposed that the vasculopathy of NF-1 patients results from abnormal neuro bromin function that leads to excessive proliferation of vascular smooth muscle cells during normal maintenance of the vessel. Conversely, even though neuro bromin is known to be expressed in vascular smooth muscle cells, little is known about its function relating to controlling endothelial cell proliferation. 8 Interestingly, despite the proximity of the NF-1 gene (17q11.2) to the gene for familial moyamoya disease (17q25), NF-1 does not participate in occurrences of moyamoya disease. 9 MMD was rst described in 1957 and, since this initial report, much has been described regarding the clinical characteristics of the disease. Nonetheless, its etiology continues to be ill-de ned. 10 MMD is more frequently observed in the Japanese population, with an estimated incidence of one new case per 1,000,000 individuals per year. MMD more frequently a ects children younger than 10 years.
11
In children, cerebral ischemia has been the most common presentation of MMD. In a study on 143 pediatric patients with MMD in North America, Scott et al. 12 observed that nearly all the patients had clinical symptoms of aneurysm or transitory ischemic attacks, and similar results have been reported in European studies. 13 In a cohort study on 316 children with NF-1, Rosser et al. 3 observed cerebral vasculopathy in eight of them (2.5%), with only two cases (0.6%) also presenting MMS.
Most patients with NF-1 associated with vascular lesions are asymptomatic.
14 When symptoms are present, they include neurological ndings such as paresthesia, headache, epileptic seizures, hemianopsia, nystagmus, aphasia, dysphasia and borderline mental level. 15 Surgical intervention has become the treatment of choice for patients with MMD, and particularly surgical revascularization in order to increase the blood ow to the hypoperfused cortex. 5, 16 CONCLUSION e present report describes an additional case of associated NF-1 and MMS in a pediatric patient. Although this association is relatively uncommon, MMS is a potentially severe disease that may evolve with an unfavorable neurological course. us, the hypothesis that this association may be present should be considered in cases of patients with NF-1 and focal neurological symptoms, so that proper care can be promptly provided.
